Infectious Diseases Research

Below are current clinical trials.

152 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study to Evaluate the Performance of Chembio Diagnostics Systems, Inc. DPP® Zika IgM Assay System With Fingerstick Whole Blood (MVSS CBD002-18 PRO)

   Rochester, Minn.

   The purpose of this study is to support the use of fingerstick whole blood on the Chembio DPP® Zika IgM Assay System.

2. A Study of the Effectiveness of the Electronic Nose with C. difficile Infected Stool

   Rochester, Minn.

   The purpose of this study is to see how effective a new technology called the electronic nose is in identifying specific infection (C. difficile) from stool samples, by analyzing the gasses the stool gives off.

3. Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

   Scottsdale/Phoenix, Ariz.

   The purpose of this open-label extension of CDI-001 (subsequently referred to as PRISM 3) is to evaluate the safety and efficacy in reducing recurrence of CDI in adults who had a recurrence within 8 weeks of receiving CP101 or placebo in PRISM 3. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in the extension study and administered CP101. Approximately 70 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.

4. A Study of Blood Mononuclear Cells from HIV Patients and Control Subjects

   Rochester, Minn.

   The purpose of this study is to provide the lab with a source of human PBMCs and serum from normal and HIV-1-infected individuals. We wish to analyze cells from HIV-infected and non-HIV infected individuals for levels of various proteins and mRNAs that are relevant to HIV research.

5. Extent of Donor Site Morbidity after Scaphoid Repair Surgery Using the Medial Femoral Condyle

   Rochester, Minn.

   The purpose of the study is to determine the extent of donor site morbidity after harvesting the medial femoral condyle for scaphoid nonunion treatment. The outcomes being measured are: superficial infection, deep infection, pain (short term), pain (long term), knee function and quality of  scar.

6. Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

   Scottsdale/Phoenix, Ariz.

   This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated interferon and RBV. The primary study hypothesis is that in at least one of the study arms, the percentage of participants achieving sustained viral response 12 weeks after the end of all study treatment (SVR12) will be superior to 58%.

7. Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis

   Rochester, Minn.

   The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo.

8. Genetic Expression in Osteolysis, Infection, Arthrofibrosis & Metal Reactions in THA & TKA: A Microarray Analysis to Characterize Individual Host Response to the Molecular Mechanisms of Loosening and Arthrofibrosis

   Rochester, Minn.

   This study is being conducted to determine gene and protein expression profiles (i.e. which genes and proteins are turned off and on) of those with a possibility of developing osteolysis, infection, arthrofibrosis or metallosis of their THA/TKA.

9. A Study to Evaluate Clinical Performance of the Aptima® CMV Quant Assay on the Panther® System

   Rochester, Minn.

   The purpose of this study is to evaluate the clinical performance of the Aptima CMV Quant assay on the Panther system in ethylenediaminetetraacetic acid (EDTA) plasma samples from solid organ transplantation recipients (SOTR) and hematopoietic stem cell transplant recipients (HSCTR).

    

10. A Study of MG1-E6E7 with Ad-E6E7 and Atezolizumab in Patients with HPV Associated Cancers

    Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

    The purpose of this study is to determine the safety, toxicity and maximum tolerated dose (MTD) / maximum feasible dose (MFD) of Ad/MG1-E6E7, and sequential treatment with atezolizumab in patients with HPV associated cancers.